Filing Details

Accession Number:
0001062993-23-023291
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-29 17:24:55
Reporting Period:
2023-12-27
Accepted Time:
2023-12-29 17:24:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1620463 Athira Pharma Inc. ATHA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1249675 Ltd Fund Master Sciences Life Perceptive 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-27 32,134 $2.28 4,829,412 No 4 P Indirect See Footnote
Common Stock Acquisiton 2023-12-28 409,598 $2.44 5,239,010 No 4 P Indirect See Footnote
Common Stock Acquisiton 2023-12-29 163,954 $2.38 5,402,964 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.195 to $2.31, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
  2. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.265 to $2.50, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
  3. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.295 to $2.44, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
  4. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor and a director of the Issuer. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.